Quorum Health CFO resigning

John Gregory | | Health Exec | Management

Michael Culotta, chief financial officer of the 31-hospital Quorum Health, has announced he’ll be leaving the post effective March 31.

Culotta has been executive vice president and CFO of Quorum since it was spun off from Community Health Systems in 2016. He had joined CHS as vice president of investor relations three years earlier. Prior to that, he spent six years as CFO at PharMerica, a pharmacy services company for long-term care facilities, as well as serving as CFO at LifePoint Hospitals.

“Mr. Culotta has served Quorum Health since our spin-off from Community Health Systems, Inc., and, on behalf of the Company, we appreciate his service and contributions over the years,” Quorum president and CEO Thomas Miller said in a statement.

Taking his place will be Alfred Lumsdaine, who since 2016 has been working as president of population health for Atlanta-based health and wellness engagement platform Sharecare. He does bring CFO experience from his work with Tivity Health, a provider of fitness programs.

“I am pleased that we have found such a qualified CFO in Mr. Lumsdaine and expect the transition will be smooth as he moves into the CFO role upon Mike’s departure,” Miller said.

Lumsdaine will assume the role of executive vice president of finance on Feb. 12, then take over the CFO position when Culotta steps down. Culotta will continue working with Quorum as a consultant.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.